A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Description

The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

Conditions

Type 2 Diabetes Mellitus

Talk to us

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Condition
Type 2 Diabetes Mellitus
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Honor Health Research Institute, Scottsdale, Arizona, United States, 85258

Los Angeles

Children's Hospital Los Angeles, Los Angeles, California, United States, 90027

Tampa

University of South Florida, Tampa, Florida, United States, 33624

Atlanta

Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia, United States, 30329

Columbus

Centricity Research Columbus Endocrinology, Columbus, Georgia, United States, 31904

Baltimore

Johns Hopkins Hospital, Baltimore, Maryland, United States, 21287

Boston

Joslin Diabetes Center, Boston, Massachusetts, United States, 02215

Buffalo

UBMD Pediatrics, Buffalo, New York, United States, 14203

New York

NYU Langone, New York, New York, United States, 10016

Cincinnati

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229-3039

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months
  • * Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening
  • * Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m²)
  • * Participants are insulin naïve or have been without insulin treatment for at least 3 months prior to screening
  • * Have had a severe hypoglycemia in the past 6 months
  • * Have a history of renal impairment
  • * Have had a blood transfusion or severe blood loss within last 90 days
  • * Have had a significant weight gain or loss in the last 90 days
  • * Have a history of an active or untreated malignancy
  • * Are receiving or received systemic glucocorticoid therapy
  • * Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product

Ages Eligible for Study

10 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2026-11